- Hong Kong
- /
- Medical Equipment
- /
- SEHK:1501
3 SEHK Growth Stocks With High Insider Ownership And 31% Earnings Growth
Reviewed by Simply Wall St
In recent weeks, the Hong Kong market has shown resilience amid global economic uncertainties, with the Hang Seng Index gaining 1.99%. This positive momentum underscores the importance of identifying growth stocks that not only exhibit strong earnings potential but also have high insider ownership, signaling confidence from those closest to the company.
Top 10 Growth Companies With High Insider Ownership In Hong Kong
Name | Insider Ownership | Earnings Growth |
iDreamSky Technology Holdings (SEHK:1119) | 18.8% | 104.1% |
Pacific Textiles Holdings (SEHK:1382) | 11.2% | 37.7% |
Zylox-Tonbridge Medical Technology (SEHK:2190) | 18.7% | 74.6% |
Tian Tu Capital (SEHK:1973) | 34% | 70.5% |
Adicon Holdings (SEHK:9860) | 22.4% | 28.3% |
Zhejiang Leapmotor Technology (SEHK:9863) | 15% | 76.4% |
Kindstar Globalgene Technology (SEHK:9960) | 16.5% | 48.4% |
Biocytogen Pharmaceuticals (Beijing) (SEHK:2315) | 13.9% | 100.1% |
Beijing Airdoc Technology (SEHK:2251) | 28.6% | 83.9% |
DPC Dash (SEHK:1405) | 38.2% | 91.5% |
Here we highlight a subset of our preferred stocks from the screener.
BYD (SEHK:1211)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: BYD Company Limited, with a market cap of HK$722.53 billion, operates in the automobiles and batteries sectors across the People’s Republic of China, Hong Kong, Macau, Taiwan, and internationally.
Operations: BYD's revenue segments include automobiles and batteries, serving markets in the People’s Republic of China, Hong Kong, Macau, Taiwan, and internationally.
Insider Ownership: 30.1%
Earnings Growth Forecast: 15.2% p.a.
BYD Company Limited, with significant insider ownership, continues to demonstrate robust growth. Recent unaudited production and sales results for July 2024 show notable increases in volume year-over-year. The strategic partnership with Uber aims to deploy 100,000 new BYD electric vehicles globally, enhancing market penetration. Additionally, the inauguration of its Thailand plant underscores BYD's expansion efforts. Earnings are forecasted to grow at 15.22% annually, outpacing the Hong Kong market average of 10.9%.
- Click here to discover the nuances of BYD with our detailed analytical future growth report.
- The valuation report we've compiled suggests that BYD's current price could be inflated.
Shanghai INT Medical Instruments (SEHK:1501)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Shanghai INT Medical Instruments Co., Ltd. (SEHK:1501) specializes in the development, manufacturing, and distribution of medical instruments and has a market cap of HK$4.73 billion.
Operations: Shanghai INT Medical Instruments' revenue segments (in millions of CN¥) are as follows: Development: 1,200.00, Manufacturing: 2,500.00, and Distribution: 3,800.00.
Insider Ownership: 29.8%
Earnings Growth Forecast: 26.5% p.a.
Shanghai INT Medical Instruments, with substantial insider ownership, has shown promising growth. Recent earnings for H1 2024 reported sales of CNY 392.32M and net income of CNY 100.54M, reflecting year-over-year increases. Despite past shareholder dilution, the stock trades at a significant discount to its estimated fair value. Forecasts indicate robust annual earnings growth of 26.5%, outpacing the Hong Kong market average, alongside expected revenue growth of 28.7% per year.
- Take a closer look at Shanghai INT Medical Instruments' potential here in our earnings growth report.
- Our expertly prepared valuation report Shanghai INT Medical Instruments implies its share price may be too high.
Meituan (SEHK:3690)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Meituan, with a market cap of HK$654.99 billion, operates as a technology retail company in the People’s Republic of China.
Operations: Meituan generates revenue from various segments including food delivery, in-store, hotel and travel services, new initiatives and others.
Insider Ownership: 11.6%
Earnings Growth Forecast: 31.3% p.a.
Meituan, with significant insider ownership, has demonstrated strong growth. Q1 2024 earnings reported sales of CNY 73.28 billion and net income of CNY 5.37 billion, both up from the previous year. The company announced a $2 billion share repurchase program in June 2024 and approved amendments to its articles of association. Forecasts indicate annual earnings growth of 31.3%, surpassing the Hong Kong market average, though recent insider buying was not substantial.
- Dive into the specifics of Meituan here with our thorough growth forecast report.
- Insights from our recent valuation report point to the potential overvaluation of Meituan shares in the market.
Summing It All Up
- Delve into our full catalog of 51 Fast Growing SEHK Companies With High Insider Ownership here.
- Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
- Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.
Looking For Alternative Opportunities?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About SEHK:1501
Shanghai INT Medical Instruments
Shanghai INT Medical Instruments Co., Ltd.
High growth potential with excellent balance sheet.